Therefore, PD-L1 blockade may not restore antitumor immunity in pancreatic cancer, as VISTA still exerts its inhibitory effects by inducing downregulation of cytokine production in TILs [122]. This evidence concerns the gene CD274 and pancreatic neoplasm.